← Teva Pharmaceutical Industries Limited (TEVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Teva Pharmaceutical Industries Limited (TEVA)
Pharmaceutical Preparations · market cap $46.0B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Teva Pharmaceutical Industries (TEVA) is a large-cap Israeli multinational with ~36,800 employees and a $40B market cap, primarily known as a global generics leader but maintaining a meaningful branded and pipeline portfolio. The company returned to profitability in 2025 with $1.41B net income on $17.26B revenue, carries net cash of approximately $1.13B, and has two high-importance Phase 3 readouts expected in the second half of 2026.
The catalyst path
- 2026-10-31 (est.)Phase 3 · TEV-56248imp 9/10
- 2026-11-03Earningsimp 5/10
- 2027-02-15 (est.)PDUFAimp 8/10
- 2027-06-30 (est.)Phase 3 · Deutetrabenazineimp 9/10
- 2027-08-27Patent Expiry · rasagiline mesylate 1.0 mgimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| rasagiline mesylate 1.0 mg | Phase 3 | Parkinson's Disease |
| 40 mg glatiramer acetate | Phase 2 | Amyotrophic Lateral Sclerosis |
| Nebulized IVX-0142 | Phase 2 | Asthma |
| BDP | Phase 3 | Allergic Rhinitis |
| TEV-56248 | Phase 3 | Asthma |
| laquinimod 0.3 | Phase 2 | Relapsing Remitting Multiple Sclerosis |
| Tizanidine (sublingual or oral) | Phase 2 | Muscle Spasticity |
| 1.0 mg rasagiline mesylate | Phase 3 | Parkinson's Disease |
| Non-Oral Corticosteroid (non-OCS) Asthma Medication | Phase 3 | Asthma |
| BDP HFA | Phase 3 | Seasonal Allergic Rhinitis |
| Beclomethasone Dipropionate 640 | Phase 3 | Persistent Asthma |
| TEV-53408 | Phase 2 | Celiac Disease |
| CEP-18770 | Phase 2 | Multiple Myeloma |
| TV-44749 | Phase 3 | Schizophrenia |
| TV-1380 150 mg | Phase 2 | Cocaine Addiction |
| desogestrel/ethinyl estradiol and ethinyl estradiol | Phase 2 | Hemostasis |
| Beclomethasone dipropionate HFA Nasal Aerosol | Phase 2 | Seasonal Allergic Rhinitis |
| SD-809 | Phase 3 | Chorea |
| Mometasone furoate | Phase 2 | Seasonal Allergic Rhinitis |
| Fluticasone Propionate and Salmeterol Inhalation Powder | Phase 3 | Asthma |
Price & technical context
3-month
+12.0%
6-month
+31.4%
12-month
+97.2%
52-wk range
$18.95–$40.22
vs 50-day MA
+7.0%
vs 200-day MA
+17.4%
Realized vol
70.4%
Max drawdown
-43.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TEVA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.